Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.

Lee P, Hegele RA.

Expert Opin Investig Drugs. 2013 Nov;22(11):1411-23. doi: 10.1517/13543784.2013.822485. Epub 2013 Jul 26. Review.

PMID:
23889692
2.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
3.

Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.

Yoon CH, Watson K.

Ann Pharmacother. 2014 Feb;48(2):238-49. doi: 10.1177/1060028013511425. Epub 2013 Nov 6. Review.

PMID:
24259646
4.
5.

New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?

Sahebkar A, Watts GF.

Cardiovasc Drugs Ther. 2013 Dec;27(6):559-67. doi: 10.1007/s10557-013-6479-4. Review.

PMID:
23913122
6.

Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.

Tavori H, Melone M, Rashid S.

Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1137-44. doi: 10.1586/14779072.2014.954551. Review. Erratum in: Expert Rev Cardiovasc Ther. 2014 Dec;12(12):1491.

PMID:
25244623
7.

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA.

J Am Coll Cardiol. 2012 Jun 19;59(25):2344-53. doi: 10.1016/j.jacc.2012.03.007. Epub 2012 Mar 28.

9.

Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.

Stein EA, Swergold GD.

Curr Atheroscler Rep. 2013 Mar;15(3):310. doi: 10.1007/s11883-013-0310-3. Review.

PMID:
23371064
10.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.

Joseph L, Robinson JG.

Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):19-31. doi: 10.1016/j.pcad.2015.04.004. Epub 2015 May 1. Review.

PMID:
25936907
11.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) and LDL lowering in the contemporary management of dyslipidemia.

Switzer MP, Nwosu AC, Juan ZS, Mukherjee D.

Cardiovasc Hematol Agents Med Chem. 2013 Dec;11(4):281-8. Review.

PMID:
24164109
12.

New therapies to reduce low-density lipoprotein cholesterol.

Wierzbicki AS, Viljoen A, Hardman TC, Mikhailidis DP.

Curr Opin Cardiol. 2013 Jul;28(4):452-7. doi: 10.1097/HCO.0b013e3283605fa2. Review.

PMID:
23736819
13.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG.

Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7.

14.

PCSK9: From discovery to therapeutic applications.

Farnier M.

Arch Cardiovasc Dis. 2014 Jan;107(1):58-66. doi: 10.1016/j.acvd.2013.10.007. Epub 2013 Dec 27. Review.

15.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
16.

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA.

JAMA. 2012 Dec 19;308(23):2497-506. doi: 10.1001/jama.2012.25790.

PMID:
23128163
17.

PCSK9 antibodies for the treatment of hypercholesterolemia.

Gouni-Berthold I, Berthold HK.

Nutrients. 2014 Dec 1;6(12):5517-33. doi: 10.3390/nu6125517. Review.

18.

Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?

Dragan S, Serban MC, Banach M.

J Cardiovasc Pharmacol Ther. 2015 Mar;20(2):157-68. doi: 10.1177/1074248414539562. Epub 2014 Jun 17. Review.

PMID:
24938457
19.

Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.

Cicero AF, Tartagni E, Ertek S.

Expert Opin Biol Ther. 2014 Jun;14(6):863-8. doi: 10.1517/14712598.2014.902929. Epub 2014 Mar 24. Review.

PMID:
24661068
20.

Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology.

Page MM, Watts GF.

Expert Opin Drug Metab Toxicol. 2015;11(9):1505-15. doi: 10.1517/17425255.2015.1073712. Review.

PMID:
26293511
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk